Tuesday, December 12, 2017 9:56:21 PM
OMHE gave conservative timeframe of three years as any public company would do but in reality this will happen sooner due to the following reasons:
(1) OMHE is reformulating its most successful (almost 4 decades old) proprietary formularies to include cannabidiol (CBD); so therapeutic is not new and has a proven record.
(2) OMHE is using FDA regulations-savvy, ‘fast-track’ pipeline strategy & will be in a position to partner for late-phase development. Minimum approval timeframe for phase-3 is 1 year.
(3) OMHE & others understand that due to current dreadful opioids epidemic, cannabidiol drug is the best alternative, therefore processing will be faster.
(4) OMHE said on Dec 5, 2017 that "plan already in motion".
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
So IMO, approval will be granted in 2018.
OMHE PPS is heading to $1
Made Thousands into Millions..Now in Tens of Millions
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM